Drugs / TAS5315
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05335499 | Jun 2022 → Dec 2023 | chronic idiopathic urticaria | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT03605251 | Aug 2018 → Nov 2019 | rheumatoid arthritis | Taiho Pharmaceutical Co., Ltd. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS5315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05335499 ↗ |
| Action | Inhibit | “Bruton's tyrosine kinase inhibitor” PMID 37217273 ↗ May 2023 |
| Route | Oral | “Oral administration for 12 or 36 weeks” NCT03605251 ↗ |
| Target | BTK | “Bruton's tyrosine kinase inhibitor” PMID 37217273 ↗ May 2023 |